Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,301 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,832 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06013423 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | recruiting | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06072131 | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL(CRESCENDO) | recruiting | Phase 3 | 504 | Acrotech Biopharma Inc.INDUSTRY | 10 | Jul 22, 2026 |
| clinicaltrials |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07008638 | Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 32 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07094048 | Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager(CHUQUL_HO001) | recruiting | Phase 4 | 80 | CHU de Quebec-Universite LavalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07236502 | Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma(MFM) | recruiting | N/A | 184 | Medical College of WisconsinOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07429721 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. | recruiting | Early Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07441694 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms | recruiting | Phase 1 | 218 | Incyte CorporationINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT07494565 | Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL | recruiting | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07719556 | Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) | recruiting | Phase 2 | 39 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07719946 | To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers | recruiting | Phase 2 | 20 | Tata Memorial CentreOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04504526 | Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases | recruiting | Early Phase 1 | 50 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07101705 | An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies | recruiting | Early Phase 1 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07200089 | Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) | recruiting | Phase 1 | 52 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06176690 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas(CABAL2) | recruiting | Phase 1 | 90 | Baylor College of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06471738 | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | recruiting | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06855121 | The Norwegian Immunotherapy in Multiple Myeloma Study(NIMMS) | recruiting | — | 400 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype | recruiting | Phase 2 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression(MOMENTUM) | recruiting | Phase 1 / Phase 2 | 84 | AstraZenecaINDUSTRY | 9 | Jul 20, 2026 | clinicaltrials |
| NCT07205315 | A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia | recruiting | Early Phase 1 | 28 | Grit BiotechnologyINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07250646 | A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis | recruiting | Phase 1 | 28 | Aspera Biomedicines, Inc.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07620314 | Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA | recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07712848 | DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | recruiting | Phase 3 | 291 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | recruiting | Phase 1 | 15 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02416388 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR(BIG-1) | recruiting | Phase 2 / Phase 3 | 3,100 | University Hospital, AngersOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05052528 | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 36 | University of California, DavisOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
| NCT06461988 | Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | recruiting | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06565689 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 | recruiting | Phase 1 | 48 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06810778 | Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 1 / Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07224672 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis(ALANIS) | recruiting | Phase 2 | 60 | GlaxoSmithKlineINDUSTRY | 2 | Jul 17, 2026 | clinicaltrials |
| NCT07246707 | KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07392242 | A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01515527 | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04022239 | Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant | recruiting | Phase 1 / Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04712539 | Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04968834 | Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens | recruiting | — | 300 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05010772 | Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | recruiting | Phase 1 | 125 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05469893 | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | recruiting | Phase 2 | 52 | Irene Ghobrial, MDOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05929612 | A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06102330 | Multicenter HomeVENT: Home Values and Experiences Navigation Track(HomeVENT) | recruiting | N/A | 600 | Johns Hopkins UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06121843 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 187 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT06207812 | Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06469307 | Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)(DIVERSE) | recruiting | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06498973 | Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant | recruiting | Phase 1 | 43 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06533748 | Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | recruiting | Phase 2 | 128 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06941324 | Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 22, 2026source: clinicaltrials